DADD, death activator death domain protein

Details DADD, death activator death domain protein DADD, death activator death domain protein

2005-05-17

2005-05-17

Canella, Karen A. (Department: 1642)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C435S325000, C435S254110, C536S023100, C536S023500

Reexamination Certificate

active

06893838

ABSTRACT:
Polynucleotides encoding DADD protein are also disclosed, along with vectors, host cells, and methods of making DADD protein. Methods of identifying inhibitors of DADD death domain binding and inhibitors identified by such methods are also disclosed.

REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4837028 (1989-06-01), Allen
patent: 5296592 (1994-03-01), Dower et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 5616491 (1997-04-01), Mak et al.
patent: 5627059 (1997-05-01), Capecchi et al.
patent: 5631153 (1997-05-01), Capecchi et al.
patent: 5679523 (1997-10-01), Li et al.
patent: 308378 (1989-03-01), None
patent: 393438 (1990-10-01), None
patent: 433900 (1991-06-01), None
patent: 526905 (1993-02-01), None
patent: 568925 (1993-11-01), None
patent: 649464 (1995-04-01), None
patent: WO 9103553 (1991-03-01), None
patent: WO 9319777 (1993-10-01), None
patent: WO 9636730 (1996-11-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Houdebine, Journal of Biotechnology, 1994, vol. 34, pp. 269-287.*
Verma et al (Nature, 1997, vol. 389, pp. 239-242).*
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101).*
Orkin et al (“Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).*
Lehningen “Biochemistry” 1975 p. 962, Worth Publishers, Inc, New York, NY.*
Current Protocols in Molecular Biology 1990, ed—Ausubel et al p. 16.7.1-16.7.8.*
Genbank Accession No: AA507436 (Aug. 18, 1997).*
Genbank Accession No: AA631067 (Oct. 31, 1997).*
Genbank Accession No. N39432 (Jan. 19, 1996).*
Genbank Accession No. N55392 (Feb. 20, 1996).*
Genbank Accession No. N50632 (Feb. 14, 1996).*
Genbank Accession No. R13288 (Apr. 12, 1995).*
Genbank Accession No. AA118566 (Nov. 19, 1996).*
Genbank Accession No. AA714504 (Dec. 29, 1997).*
Genbank Accession No. AA642327 (Nov. 13, 1997).*
Albert, Paul R. and Morris, Stephen J. “Antisense knockouts: molecular scalpets for the dissection of signal transduction”Trends Pharmacol. Sci.15(7):250-54 (1994).
Chinnaiyan, Arul M. et al. “FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis”Cell81:505-12 (May 19, 1995).
Chinnaiyan, Arul M. et al, “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95”Science274:990-92 (Nov. 8, 1996).
Clark, Andrew G. et al, “Nature screen: An efficient method for screening natural populations ofDrosophiliafor targeted P-element insertions”Proc. Natl. Acad. Sci. USA91(2):719-22 (Jan. 1994).
Genbank Accession No. AA631067 for nq77c12.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1158358 3′, mRNA sequence.
Genbank Database Accession No. A1022161 for ow68g09.x1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:1652032 3′, mRNA sequence.
Hampel, Arnold : The Halrpin Ribozyme: Discovery, Two-Dimensional Model, and Development for Gene TherapyProg. Nucleic Acid Res. Mol. Biol.58:1-39 (1998).
Hsu, Hailing et al., “The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-kB Activation”Cell81:495-504 (May 19, 1995).
Lavrovsky, Yan et al. “Therapeutic Potential and Mechanism of Action of Oligonucleotides and Ribosomes”Biochem. Mol. Med.62(1):11-22 (1997).
Mansour, Suzanne L. et al. “Disruption of the proto-oncogeneint-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes”Nature336:348-52 (Nov. 24, 1988).
Pan, Guohua et al. “The Receptor for the Cylotoxic Ligand TRAIL”Science276:111-13 (Apr. 4, 1997).
Plasterk, Ronald H.A. “Reverse Genetics ofCaenorhabditis elegans” Bioessays14(9):629-33 (Sep. 1992).
Schall, Thomas J. et al. “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor”Cell61:361-370 (Apr. 20,1990).
Schievelia, Andrea R. et al. “MADD, a Novel Death Domain Protein That Interacts with the Type 1 Tumor Necrosis Factor Receptor and Activates Mitogen-activated Protein Kinase”J. Biol. Chem.272(18):12063-75 (1997).
Stanger, Ben Z. et al. “RIP: A Novel Protein Containing a Death Domain That Interacts with Fas/APO-1 (CD95) in Yeast and Causes Cell Death”Cell81:513-23 (May 19, 1995).
Tartaglia, Louis A. et al. “A Novel Domain within the 55 kd TNF Receptor Signals Cell Death”Cell74:845-53 (Sep. 10, 1993).
Zwaal, Richard R. et al. “Target-selected gene inactivation inCaenorhabditis elegansby using a frozen transposon insertion mutant bank”Proc. Natl. Acad. Sci. USA90(16):7431-35 (Aug. 1993).

Affiliated with

Also associated with

Rating

DADD, death activator death domain protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DADD, death activator death domain protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DADD, death activator death domain protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3390034